Skip to main content

Table 1 Demographic and treatment characteristics of the study population

From: Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment

Variables

TRS

non-TRS

p

Number of patients, n

478

808

Male, n (%)

284 (59)

430 (53)

0.031

Age, years; mean (SD)

48.7 (15.0)

48.7 (16.9)

0.99

Serum concentration, nmol/L; mean (95%CI)

1201 (1162,1240)

64 (30, 98)

Dose, mg/day; mean (95%CI)

335 (320, 350)

3.3 (3.2, 3.4)

History of TDM measurements, n; median (IQR)

14 (5, 36)

3 (1.8, 7)

TDM duration, years; median (IQR)

4.3 (0.7, 11.8)

0.8 (0.04, 4.8)

  1. IQR Interquartile range, SD Standard deviation, TDM Therapeutic drug monitoring, TRS treatment resistant schizophrenia. TRS and non-TRS groups comprised of patients who were treated with clozapine and risperidone, respectively